Initial digest — TERT receipt

what this node claims

Initial digest — TERT

AlphaFold v6 prediction landed for **TERT** (Telomerase reverse transcriptase). UniProt accession: `O14746`. Lane: `longevity`. Mean per-residue pLDDT: **80.2**. Activator design — exquisite tissue specificity require...

Open source surface

vertical proof spine

evidence / risk instrument

39%

thin proof

low debt pressure 29%

28%structuredebt

pLDDT pending

55%evidencethin

grade C

0%gatesdebt

0/5 gates

100%riskstrong

0 hard flags

22%exportdebt

no export

33%lineagedebt

incomplete spine

proof completeness

33% missing target, alphafold_metric, candidate, export

01 target
02 fold
03 alphafold metric
04 candidate
05 finding
06 export

Metrics and receipt inputs

confidence: 0.6
evidence refs: 1

AlphaFold metrics visual

Confident backbone model

80.2

1132 residues / min 21.31 / max 98.56 / source alphafold db

Very high 58.3% 660 residues / >=90

Confident 21.1% 239 residues / 70-89

Low 3.9% 44 residues / 50-69

Very low 16.7% 189 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 1132 of 1132 residues.

residues 179-323 / mean 28.06
residues 417-443 / mean 38.37
residues 636-654 / mean 47.04
residues 367-380 / mean 46.25

proof debt register

Visible limits, not hidden cleanup.

29%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

high low evidence grade attach graded finding with source-linked evidence

low computational-only status add independent evidence, challenge result, or witness review before strengthening

medium no candidate yet leave visible until a stronger public receipt resolves it

Initial digest — TERT